Novel therapeutic strategies for MLL-rearranged leukemias.

Abstract excerpt

MLL rearrangement is one of the key drivers and generally regarded as an independent poor prognostic marker in acute leukemias. The standard of care for MLL-rearranged (MLL-r) leukemias has remained largely unchanged for the past 50 years despite unsatisfying clinical outcomes, so there is an urgent need for novel therapeutic strategies. An increasing body of evidence demonstrates that a vast number of epigenetic...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Disease Management
• Share to Drug Evaluation, Preclinical
• Share to Gene Expression Regulation, Leukemic